BRAVATO (ex-V3SWG)
Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO; ex-V3SWG) In recognition of the increasing importance of viral vectors for the development of new vaccines and the need to understand their associated…
Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO; ex-V3SWG) In recognition of the increasing importance of viral vectors for the development of new vaccines and the need to understand their associated…
Safety Platform for Emergency vACcines (SPEAC) The Coalition for Epidemic Preparedness Innovations (CEPI) mission is to stimulate and accelerate the development of vaccines against emerging infectious diseases and enable access…
Global Alignment of Immunization Safety Assessment in Pregnancy (GAIA) Immunization in pregnancy is a promising public health strategy to reduce illness and death among pregnant women and young infants. This…
Systematic Observational Method for Narcolepsy and Influenza Immunization Assessment (SOMNIA) Background: In 2010, a safety signal was detected for narcolepsy following vaccination with Pandemrix, an AS03-adjuvanted monovalent pandemic H1N1 influenza…
Global Research in Paediatrics (GRiP) Randomised controlled trials (RCTs) are considered the gold standard for assessing the efficacy of drugs prior to their approval for use in the general population…
The Brighton Collaboration (BC) Viral Vector Vaccines Safety Working Group (V3SWG) was renamed to Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) in July of 2020, so as to expand beyond…